Kornimate/medical-research-clean huggingface dataset:
validation of fibrosis quantification using t1 mapping against histology as reference and comparison with fibrosis biomarkers

Conditions: Myocardial Fibrosis

Summary: myocardial fibrosis is recognized as the pathologic entity of extracellular matrix remodeling. diffuse, reactive fibrosis is increasingly recognized in a variety of conditions despite the absence of ischemia. regardless of the etiology, fibrosis leads to increased myocardial stiffness thereby promoting cardiac dysfunction. this dysfunction may present clinically with symptoms of cardiac failure although this is often a subclinical disease. various imaging modalities and collagen biomarkers have been used as surrogate markers to assess the presence, extent, and turnover of myocardial fibrosis. techniques using echocardiography, cardiac magnetic resonance, and nuclear imaging have been developed to detect early features of systolic and diastolic left ventricular dysfunction and impaired contractile reserve. further identification of diffuse reactive fibrosis may be possible with evolving cardiac magnetic resonance and molecular techniques. the goal of this protocol is to validate cardiac magnetic resonance imaging as a new tool for fibrosis quantification against histology as standard of reference.


Eligibility criteria:
inclusion criteria: * all patients who require surgical aortic valve replacement , which will benefit from an mri to measure fibrosis in the months preceding the surgery. * patient submitted to the social security scheme * patient agreeing to participate in the study and who signed the informed consent. exclusion criteria: * a history of myocardial * unstable patients requiring treatment with catecholamines. * hepatocellular insufficiency of alcoholic origin * severe renal impairment * appearance before examining coronary syndrome at high risk, defined according to international recommendations. * history of known allergy to gadolinium at diagnosis * pregnant or lactating * patient \< 18 years
serotonin, leptin and adiponectin level in patients with postpartum depression: controlled study

Conditions: Postpartum Depression

Summary: after vaginal delivery, all of the participants will evaluate by using edinburg depression scale and venous blood sample will obtain. postpartum depression will consider the result of scale 13 and above according to turkhish translate. then leptin, adiponectin and serotonin level will compare between depressed and nondepressed women.


Eligibility criteria:
inclusion criteria: * all women who gave birth exclusion criteria: * women with previously diagnosed depression and any psychiatric disorders * women with previously take antidepressan and antipshycothic * women giving birth to children with anomalies * women with undertake surgery for peripartum hemorrhage
genomic profiling of pancreatic cystic tumors

Conditions: Pancreatic Cyst

Summary: this study aims to find out whether quantitative and qualitative analysis, including genetic mutation analysis, of samples obtained from patients with pancreatic cysts is associated with the risk of malignancy, and helpful in the differential diagnosis of mucinous and serous cysts. the study design is a single-arm prospective cohort observational study. using blood, pancreatic cyst fluid, and pancreatic cyst tissue, genetic mutation analysis and measurement of various biomarkers are performed, and the relationship between these and malignancy or whether they are helpful in distinguishing mucinous and serous cysts is analyzed. the primary outcome is genetic variants of pancreatic cysts associated with malignancy. the secondary outcomes are factors including genetic variants that differentiate mucinous from serous cysts.

pancreatic cysts, especially mucinous cysts, are precancerous lesions that can cause pancreatic cancer, and follow-up surveillance is important. however, there is a lack of clear medical evidence for the proper method and timing of follow-up, so the current follow-up strategies rely heavily on the opinions of experts. although mucinous pancreatic cyst is known as a precancerous lesion, the incidence of cancer is about 1-5%. therefore, if the risk of malignant disease can be more accurately predicted in patients with pancreatic cysts, patients with a high risk of malignant disease can be more intensively monitored and improved survival rates can be expected through early detection of pancreatic cancer. in addition, unnecessary medical resource consumption can be reduced by increasing the follow-up interval of pancreatic cyst patients with low risk of malignancy or not following them at all. to this end, in addition to imaging characteristics of pancreatic cysts, which are currently suggested as risk factors for malignancy in most guidelines for pancreatic cysts, differential diagnosis of pancreatic cysts based on new biomarkers such as genetic mutations and malignant risk assessment are necessary. therefore, in this study, the investigators comprehensively analyze the blood, pancreatic cyst fluid, and pancreatic cyst tissue of patients with pancreatic cysts to explore biomarkers including genetic mutations that are helpful in the differential diagnosis of pancreatic cyst and the diagnosis of malignant tumors.

Eligibility criteria:
inclusion criteria: * pancreatic cyst patients undergoing cyst aspiration or biopsy or surgical resection * patients who gave written informed consent exclusion criteria: * anyone who has not signed a written consent form. * patients deemed unsuitable for research (severe infection, drug abuse, severe mental illness, etc.)
clinical evaluation of the photoallergy potential of atralin gel

Conditions: Healthy

Summary: to assess the potential of tretinoin gel 0.05% and its vehicle to produce photoallergic reactions, measured as skin reactions following induction and challenge.


Eligibility criteria:
inclusion criteria: * normal, healthy volunteers * 18 years of age and older exclusion criteria: * less than 18 years of age

Keywords: tretinoin exposure to uv light phototoxicity safety when exposed to sunlight
a study of the efficacy and safety of vibegron (mk-4618) in participants with overactive bladder (oab) (mk-4618-008)

Conditions: Urinary Bladder, Overactive

Summary: this is a 2-part study to assess if vibegron (mk-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (oab). the primary hypothesis of the base study is that administration of vibegron demonstrates a dose-related reduction, compared with placebo, in average number of daily micturitions in participants with oab after 8 weeks of treatment.

all participants received placebo (run-in) for 1 week prior to randomization to parts 1 and 2. participants who complete the base study may be screened for a year-long, multicenter extension for assessment of long-term safety and efficacy.

Eligibility criteria:
inclusion criteria: * if participant is of reproductive potential, must agree to remain abstinent or use (or have his/her partner use) 2 acceptable methods of birth control within the projected duration of the study * clinical history of oab for at least 3 months and meets either the oab wet or oab dry criteria * is able to read, understand and complete questionnaires and voiding diaries without assistance * is ambulatory and in good general physical and mental health * no clinically significant electrocardiogram or laboratory abnormality exclusion criteria: * if female, is currently pregnant or breast-feeding, or expecting to conceive within the projected duration of the study * evidence of diabetes insipidus, uncontrolled hyperglycemia or uncontrolled hypercalcemia * allergy, intolerance, or history of a significant clinical or laboratory adverse experience associated with any of the active or inactive components of tolterodine er or vibegron (mk-4618) formulation; or has a history or active diagnosis of any condition contraindicated in the tolterodine er prescribing label * has lower urinary tract pathology that could be responsible for urgency, frequency, or incontinence * history of injury, surgery, or neurodegenerative diseases (e.g., multiple sclerosis) that could affect the lower urinary tract or its nerve supply * history of continual urine leakage * surgery to correct stress urinary incontinence or pelvic organ prolapse within 6 months * known history of elevated postvoid residual * bladder training or electrostimulation within 2 weeks or is planning to initiate either procedure during the study * active or recurrent (\>6 episodes per year) urinary tract infections * current hematuria * required use of an indwelling catheter or requires intermittent catheterization * history of fecal incontinence

Keywords: overactive bladder mk-4618 tolterodine
epicheck and short-term intensive chemoresection in nmibc

Conditions: Bladder Cancer

Summary: the aim of this explorative study is to evaluate whether epicheck can be used as a predictor of tumour response to short-term, intensive chemoresection with mitomycin.

the study will be conducted as an exploratory, prospective observational study. participants consists of patients referred to short-term, intensive chemoresection due to recurrent nmibc. the treatment adhere to the regimen described in the nicsa trial with the clinicaltrials.gov identifier nct03348969. treatment consists of short-term, intensive chemoresection with mitomycin; 40 mg is administered intravesically three times a week for two weeks. to evaluate tumour response, an early cystoscopy is performed in the outpatient clinic one to two months after treatment completion. no visible tumour and residual tumour with benign histology is considered complete response. residual tumour tissue with neoplastic histology is considered incomplete response and will be treated with turbt or tumour fulguration. subsequently patients continue a standardized follow-up program as danish guidelines prescribe which is initiated after four months.

Eligibility criteria:
inclusion criteria: * patients with a known history of ta hg with recurrent disease * patients referred to short-term, intensive chemoresection * patients older than 18 years exclusion criteria: * known allergy or intolerance to mitomycin * incontinence or small bladder capacity (\< 100 ml) * previous pelvic radiation therapy
a registered cohort study on sma

Conditions: Spinal Muscular Atrophy

Summary: spinal muscular atrophy (sma) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord. this is a registered cohort of spinal muscular atrophy (sma) type i，ii and iii in china. this study will provide further insights into the clinical course of sma including overall survival, demographic characteristics, motor function, respiratory support, feeding and nutritional support, growth and development. the correlation of genotype and phenotype will be conducted.


Eligibility criteria:
inclusion criteria: * patients with sma types i, ii and iii * asymptomatic sma carriers * relatives of sma patients or carriers * unrelated healthy controls * participants or parent(s)/legal guardian(s) willing and able to complete the informed consent process exclusion criteria: \* participants are unable to comply with trial procedures and visit schedule
incidence of obstetric anal sphincter injuries after a protection training

Conditions: Obstetric Trauma

Summary: this is a retrospective cohort study. this two cohort study seeks to compare the incidence of obstetric anal sphincter injuries (oasis) in two time periods, before and after an educational workshop for improved perineal support.

perineal trauma during vaginal delivery is a major health issue associated with significant morbidity. it has been associated with many long term sequelae, including urinary and fecal incontinence. specifically, third and fourth degree lacerations are known risk factors for the development of fecal incontinence. due to their serious impact, third or fourth degree perineal tears are a commonly tracked adverse event in obstetric care (agency for healthcare research and quality and joint commission). as such, incidence data will soon be available to third-party payers and to the public on the internet. moreover, functional impairment after perineal lacerations continues to be a significant impetus for legal claims. thus, reducing oasis while preserving maternal and fetal outcomes is an important goal in clinical obstetrics. at the two trihealth tertiary care institutions, the overall rate of oasis is 3.5%. this is comparable, but not superior, to published rates at other centers. in fact, the literature is quite variable, with reported incidences ranging from 0.25-6%. indeed, trihealth has recently set up a task force to reduce these injuries as part of recent endeavors for quality improvement. prevention is the first step in improving these complications. this study seeks to decrease the incidence of obstetric and anal sphincter injuries that may occur during the birthing process by bringing in a notable physician to review techniques with the obstetrics residents to help avoid these injuries then observe the deliveries of the women enrolled.

Eligibility criteria:
inclusion criteria: * obstetrics resident patients * 18 years and older women who delivered vaginally between oct. 2014 and dec.2016 exclusion criteria: * women who delivered by cesarean section, preterm deliveries (less than 32 weeks), and multiple gestations
single dose flecainide for early sinus rhythm conversion of perioperative atrial fibrillation after noncardiac surgery

Conditions: Atrial Fibrillation; Surgery

Summary: investigator-initiated pilot study of single dose oral flecainide versus no flecainide for the early conversion of perioperative atrial fibrillation to sinus rhythm after noncardiac surgery.

flip-af is a prospective, randomized, open-label trial of single dose flecainide versus no flecainide in patients with perioperative atrial fibrillation after noncardiac surgery. the primary objective is to determine whether it is feasible to conduct a large randomized controlled trial assessing the efficacy and safety of single dose flecainide in this population.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * noncardiac surgery in the last 30 days requiring an overnight hospital admission; * presence of af (i.e., atrial fibrillation and/or flutter) with a ventricular heart rate of ≥ 100 beats per minute at any time within 12 hours prior to randomization; * in af at the time of randomization; and, * provided written informed consent. exclusion criteria: * history of af without normal sinus rhythm documented within 90 days prior to randomization; * hemodynamic instability; * have any one of the following contraindications to flecainide: 1. known left ventricular ejection fraction ≤ 40%; 2. myocardial infarction within the last 30 days; 3. qrs interval \>140ms; 4. allergy to flecainide; 5. severe uncorrected hypokalemia (\ 6.5 meq/l) at the time of randomization; 6. severe acute liver dysfunction or history of advanced cirrhosis; 7. severe renal insufficiency (egfr ≤ 30ml/min or dialysis); or, 8. second or third degree atrioventricular block within the last 30 days, in the absence of a pacemaker device; * unable to take oral medication; * previously enrolled in the trial.

Keywords: flecainide
respiratory capacity and swallowing function in spinal disorders: a pilot study

Conditions: Spinal Cord Injuries; Deglutition Disorders

Summary: this study is part of a larger grant, for which the overall goal is to collect measurements of liquid flow through the oropharynx (i.e., mouth and throat) during swallowing.the focus of this study is to evaluate the flow of liquids of varying consistency in the spinal disorder population.

thickened liquids are commonly used as an intervention for dysphagia (swallowing impairment). however, the field lacks a clear understanding of how liquids of different consistencies behave during swallowing. in order to improve understanding of the effectiveness of altered liquid consistency for improving dysphagia, the investigators are studying liquid flow through the oropharynx. this study explores this question in individuals with spinal cord injury. participants will swallow 20% w/v barium thickened to different consistencies (thin, slightly thick, mildly thick, moderately thick and extremely thick). swallowing will be observed under videofluoroscopy. simultaneous measures of airflow via nasal cannula will be used to study respiratory-swallow coordination in this study sample.

Eligibility criteria:
inclusion criteria: spinal cord injury at the cervical or thoracic level (t6 or higher) exclusion criteria: * prior history of swallowing, motor speech, gastro-esophageal difficulties, chronic sinusitis or taste disturbance. * neurological difficulties unrelated to spinal disorder (e.g. stroke, parkinson disease, etc). * cognitive communication difficulties that may hinder ability to participate. * current use of mechanical ventilation * external instrumentation around the head/neck that would obstruct the field of view during the videofluoroscopy exam (e.g. cervical collar). * type 1 diabetes (due to the requirement to swallow stimuli containing starch based thickeners, which carry a significant carbohydrate load). * known allergies to latex, food coloring or dental glue (due to the probability that these items will come into contact with the oral mucosa during data collection). * children and pregnant women (due to the use of radiation during the videofluoroscopic examination).
remote exercise video adaptations to maximize physical activity in childhood cancer

Conditions: Frailty; Survivorship; Childhood Cancer

Summary: the goal of this observational study is to leverage childhood cancer survivor input to adapt video content of a digital video disc-(dvd) delivered evidence-based pa intervention, originally designed for community-dwelling older adults. primary objective: - to leverage childhood cancer survivor input to adapt video content for an evidence-based remote exercise intervention.

this study is being done to update existing exercise videos to suit adult survivors of childhood cancer to help them exercise at home. patients will be asked to watch exercise videos designed for older adults and provide feedback during an interview to help researchers update the videos to childhood cancer survivors' preferences

Eligibility criteria:
inclusion criteria: * participants enrolled in the st. jude lifetime cohort (sjlife), aged 18- 39. * identifies as low active (self-reports \<2 days/week of physical activity (pa) for at least 30 minutes over the past 6 months. * participant or legal guardian is able and willing to give informed consent. * internet access exclusion criteria: * individuals who cannot speak, read, and/or understand english.
antidepressant efficacy of psychotherapy and citalopram in patients with breast cancer and major depression

Conditions: Breast Cancer; Major Depressive Episode

Summary: to provide evidence on the antidepressant efficacy of two therapeutic treatments: pharmacological treatment (citalopram) and psychotherapy treatment, in women diagnosed with breast cancer and major depression.


Eligibility criteria:
inclusion criteria: * female patients first time diagnosed with breast cancer (stage i, ii, iii, or iv) between ages 18 and 75 (both inclusive). * patients with a "moderate-severe" level of emotional distress who meet the diagnostic criteria for major depression for at least two weeks or adjustment disorder with depressive mood for at least two months, according to the diagnostic and statistical manual of mental disorders, fifth edition criteria (dsm-v), during the twelve months following the diagnose of breast cancer. * informed consent form signature exclusion criteria: * women who are pregnant or breastfeeding. * suicide risk. * metastatic brain disease. * personal history of oncological disease. * personal history of serious somatic disease (cardiac, hepatic, respiratory, endocrinological, neurological and haematological). * personal history of organic brain disorder, substance abuse/dependence. * personal history of psychotic disorder, bipolar disorder and/or mental retardation. * contraindications of citalopram treatment. * taking antidepressants after the breast cancer diagnosis. * psychotherapy treatment after breast cancer diagnosis .

Keywords: breast cancer major depressive episode antidepressant efficacy psychotherapy citalopram
atropine (0.02%, 0.04%) combined with defocus dims for moderate and high myopia control

Conditions: Myopia

Summary: to evaluate the effectiveness and safety of dims, low concentration atropine eye drops,and atropine combined with dims in controlling axial length and refraction in children with moderate to high myopia.

in this study, stratified block randomization was employed for random grouping, and the total sample size required as calculated was 410 individuals. firstly, 410 subjects were assigned id numbers ranging from 1 to 410. spss.26 statistical software was utilized to apply the "random number generator" by setting the "fixed seed number" to "20231121", and subsequently generate random numbers. once the random numbers were obtained, random sampling and grouping were conducted. this study was a multicenter trial, with block randomization stratified by center. the total sample size of 410 was distributed across 4 cities, and the samples collected in each city were randomly allocated into 5 treatment groups (groups a, b, c, d, and e), with approximately 20 individuals in each group.

Eligibility criteria:
inclusion criteria: * school-age children aged 6 to 12 years (including boundary value) * children with moderate or high myopia (subjective refraction after cycloplegia: -9.00d≤spherical equivalent (se)≤-3.00d, with-rule astigmatism (c)≤2.00d, against-rule astigmatism (c)≤1.00d, anisometropia of both eyes≤2.50d) * binocular best corrected visual acuity (bcva)≥0.8 (five-point visual acuity 4.9) * agree with the study scheme and sign the informed consent * note: if both eyes meet the inclusion criteria, the eye with higher spherical equivalent is the study eye; if one eye meets the inclusion criteria, the eye is the study eye. exclusion criteria: * used or currently using orthokeratology, multifocal contact lenses, defocusing framework lenses, atropine eye drops and other myopia control means in the past month; used red light treatment in the past * children with obvious strabismus and amblyopia * with congenital eye disease, such as congenital cataract, congenital retinal disease * secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as marfan syndrome) * had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.) * refractive medium opacity (such as corneal disease, crystal opacity, etc.) * bnormal intraocular pressure and clinical significance (iop \&lt;10 mmhg or iop \&gt;21mmhg or binocular iop difference ≥5mmhg) * fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases * optic nerve damage or congenital optic nerve dysfunction * can not be regularly checked * the adjustment range is less than 8d or obvious near difficulties * other reasons researchers think it is not suitable for inclusion in researchers
health-economic evaulation of interventional pain mangement

Conditions: Chronic Pain

Summary: to establish the cost per qaly (quality adjusted life years) gained all patients that are referred to a specialized interventional pain clinic are assessed by euroqol eq-5d to measure the health-related quality of life at the first visit and then during the following year. quality of life is calculated from eq-5d by using hte tto-validated uk-value set. with this and calculations of the cost we will be able to calculate the cost per qaly-gained which makes it possible to compare interventional pain managment to other treatments for pain patients.


Eligibility criteria:
inclusion criteria: * all patients exclusion criteria: